Czech Republic Pharmaceuticals and Healthcare Report Q3 2013:Life Sciences Market Research Reports

Life Sciences Market Research Reports

Czech Republic Pharmaceuticals and Healthcare Report Q3 2013 Aug 7th 2013, 00:00, by rnrmahesh BMI View: The Ministry of Health’s decision to reimburse the state insurer more for taking on expensive patients suggests state favouritism, but given the VzP’s longer list of high-risk patients, it is understandable. The fact that private insurers have not diversified their pools of patients has meant that the most demanding patients have ended up with the VzP, contributing to its significant debts. The insurance system must draw from other European countries, where risk is equalised to ensure coverage for all patients. Headline Expenditure Projections ? Pharmaceuticals: CZK79.60bn (US$4.07bn) in 2012 to CZK82.68bn (US$4.04bn) in 2013; 3.9% in local currency … Order / Buy a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=110310. Complete report details with Table of Contents and more @ http://www.rnrmarketresearch.com/czech-republic-pharmaceuticals-and-healthcare-report-q3-2013-market-report.html.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions